BioKryo
BioKryo is recorded as a service provider in 7 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 7 of 7 trials · Latest update first
Phase III postneoadjuvant study evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment - SASCIA
Sponsor GBG Forschungs GmbH
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo
Sponsor NSABP Foundation Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available4 trial-level findings · Read insights
- Approximately 29% of screened patients (638/2,188) were screening failures.
- Slow enrollment prompted an amendment to revise statistical planning.
- Consistently low monthly EFS event rates in 2024 led to amendment of the analysis plan to permit definitive analysis at 242 rather than 252 confirmed EFS events.
- Following FDA approval of pembrolizumab for high-risk early-stage triple-negative breast cancer, 29 US patients discontinued neoadjuvant protocol therapy to initiate pembrolizumab without being counted as EFS events.
These findings describe the trial, not the service provider’s performance or responsibility.
A randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab +/- the PI3K inhibitor inavolisib in patients with HER2-positive, HR-positive, PIK3CA mutant early breast cancer - GeparPiPPa
Sponsor GBG Forschungs GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Phase I/IIa, first-in-human, open-label, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of CLDN6 CAR-T with or without CLDN6 RNA-LPX in patients with CLDN6-positive relapsed or refractory advanced solid tumors
Sponsor BioNTech Cell & Gene Therapies GmbH
- Start (EU)
- Latest update
- Estimated end
PALLAS - PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor ABCSG GmbH
- Start (EU)
- Latest update
- Estimated end
Phase II study evaluating the addition of elacestrant, an oral selective estrogen receptor degrader (SERD), to standard-of-care olaparib in patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with gBRCA1/2 mutations – ELEMENT
Sponsor GBG Forschungs GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
TACTI-004, a double-blinded, randomized phase 3 trial in patients with advanced/metastatic non-small cell lung cancer (NSCLC) receiving eftilagimod alfa (MHC class II agonist) in combination with pembrolizumab (PD-1 antagonist) and chemotherapy.
Sponsor Immutep
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for BioKryo?
The 2026-10-09 snapshot links BioKryo to 7 distinct CTIS trials. Recorded services include storage of frozen blood samples, frozen samples, GBG Biobank storage, Laboratory services, among 5 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for BioKryo?
The most frequently recorded therapeutic areas are Solid Tumor Oncology. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to BioKryo conducted?
The linked trials record locations in 19 countries, including Germany, Spain, Belgium, Austria, Ireland. These are trial locations, not confirmed office locations or countries where BioKryo delivered services.
What can this page tell me about BioKryo's trial experience?
Browse 7 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under BioKryo. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- BioKryo GmbH